Fundamental & Clinical Pharmacology

Papers
(The H4-Index of Fundamental & Clinical Pharmacology is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Hepatoprotective and therapeutic effects of resveratrol: A focus on anti‐inflammatory and antioxidative activities40
Antiviral therapies: advances and perspectives38
Chemsex practice in France: An update in Addictovigilance data34
In vitro inhibition and molecular docking of a new ciprofloxacin‐chalcone against SARS‐CoV‐2 main protease32
Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications30
Oxidative stress and mitochondrial dysfunction following traumatic brain injury: From mechanistic view to targeted therapeutic opportunities30
Poster Abstracts29
Edaravone dexborneol protects cerebral ischemia reperfusion injury through activating Nrf2/HO‐1 signaling pathway in mice28
A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS‐CoV‐228
Poster Abstracts27
Neuropharmacology in traumatic brain injury: from preclinical to clinical neuroprotection?27
Is lithium neuroprotective? An updated mechanistic illustrated review22
The clinical meaning of levodopa equivalent daily dose in Parkinson's disease21
The possible role of CREB‐BDNF signaling pathway in neuroprotective effects of minocycline against alcohol‐induced neurodegeneration: molecular and behavioral evidences20
Psychoactive substance use among students: A cross‐sectional analysis20
Valproic acid reverses sorafenib resistance through inhibiting activated Notch/Akt signaling pathway in hepatocellular carcinoma18
Poster Abstracts17
Anti‐inflammatory effect of amitriptyline in a rat model of acetic acid‐induced colitis: the involvement of the TLR4/NF‐kB signaling pathway17
Remdesivir potently inhibits carboxylesterase‐2 through covalent modifications: signifying strong drug‐drug interactions17
0.030512094497681